186 related articles for article (PubMed ID: 25129821)
1. DJ-1: a promising marker in metastatic uveal melanoma.
Chen LL; Tian JJ; Su L; Jing Y; Zhang SC; Zhang HX; Wang XQ; Zhu CB
J Cancer Res Clin Oncol; 2015 Feb; 141(2):315-21. PubMed ID: 25129821
[TBL] [Abstract][Full Text] [Related]
2. Serum markers to detect metastatic uveal melanoma.
Barak V; Frenkel S; Kalickman I; Maniotis AJ; Folberg R; Pe'er J
Anticancer Res; 2007; 27(4A):1897-900. PubMed ID: 17649791
[TBL] [Abstract][Full Text] [Related]
3. Potential Role of Soluble c-Met as a New Candidate Biomarker of Metastatic Uveal Melanoma.
Barisione G; Fabbi M; Gino A; Queirolo P; Orgiano L; Spano L; Picasso V; Pfeffer U; Mosci C; Jager MJ; Ferrini S; Gangemi R
JAMA Ophthalmol; 2015 Sep; 133(9):1013-21. PubMed ID: 26068448
[TBL] [Abstract][Full Text] [Related]
4. Serum DJ-1/PARK 7 is a potential biomarker of choroidal nevi transformation.
Bande MF; Santiago M; Blanco MJ; Mera P; Capeans C; Rodríguez-Alvarez MX; Pardo M; Piñeiro A
Invest Ophthalmol Vis Sci; 2012 Jan; 53(1):62-7. PubMed ID: 22125279
[TBL] [Abstract][Full Text] [Related]
5. Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study.
Kadkol SS; Lin AY; Barak V; Kalickman I; Leach L; Valyi-Nagy K; Majumdar D; Setty S; Maniotis AJ; Folberg R; Pe'er J
Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):802-6. PubMed ID: 16505010
[TBL] [Abstract][Full Text] [Related]
6. ME20-S as a Potential Biomarker for the Evaluation of Uveal Melanoma.
Bande MF; Santiago M; Mera P; Piulats JM; Blanco MJ; Rodríguez-Álvarez MX; Capeans C; Piñeiro A; Pardo M
Invest Ophthalmol Vis Sci; 2015 Nov; 56(12):7007-11. PubMed ID: 26523384
[TBL] [Abstract][Full Text] [Related]
7. [Melanoma inhibitory activity (MIA). Evaluation of a new tumor-associated antigen as a serum marker for uveal melanomas].
Schaller UC; Mueller AJ; Bosserhoff AK; Haraida S; Löhrs U; Buettner R; Kampik A
Ophthalmologe; 2000 Jun; 97(6):429-32. PubMed ID: 10916387
[TBL] [Abstract][Full Text] [Related]
8. "Melanoma inhibitory activity" (MIA): a promising serological tumour marker in metastatic uveal melanoma.
Reiniger IW; Schaller UC; Haritoglou C; Hein R; Bosserhoff AK; Kampik A; Mueller AJ
Graefes Arch Clin Exp Ophthalmol; 2005 Nov; 243(11):1161-6. PubMed ID: 15906071
[TBL] [Abstract][Full Text] [Related]
9. Serum DJ-1 as a diagnostic marker and prognostic factor for pancreatic cancer.
He XY; Liu BY; Yao WY; Zhao XJ; Zheng Z; Li JF; Yu BQ; Yuan YZ
J Dig Dis; 2011 Apr; 12(2):131-7. PubMed ID: 21401899
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor-1 as a predictive biomarker for metastatic uveal melanoma in humans.
Frenkel S; Zloto O; Pe'er J; Barak V
Invest Ophthalmol Vis Sci; 2013 Jan; 54(1):490-3. PubMed ID: 23197685
[TBL] [Abstract][Full Text] [Related]
11. Receiver operating characteristic analysis: calculation for the marker 'melanoma inhibitory activity' in metastatic uveal melanoma patients.
Klingenstein A; Haritoglou I; Schaumberger MM; Nentwich MM; Hein R; Schaller UC
Melanoma Res; 2011 Aug; 21(4):352-6. PubMed ID: 21540751
[TBL] [Abstract][Full Text] [Related]
12. The characterization of the invasion phenotype of uveal melanoma tumour cells shows the presence of MUC18 and HMG-1 metastasis markers and leads to the identification of DJ-1 as a potential serum biomarker.
Pardo M; García A; Thomas B; Piñeiro A; Akoulitchev A; Dwek RA; Zitzmann N
Int J Cancer; 2006 Sep; 119(5):1014-22. PubMed ID: 16570276
[TBL] [Abstract][Full Text] [Related]
13. miRNA profiling in vitreous humor, vitreal exosomes and serum from uveal melanoma patients: Pathological and diagnostic implications.
Ragusa M; Barbagallo C; Statello L; Caltabiano R; Russo A; Puzzo L; Avitabile T; Longo A; Toro MD; Barbagallo D; Valadi H; Di Pietro C; Purrello M; Reibaldi M
Cancer Biol Ther; 2015; 16(9):1387-96. PubMed ID: 25951497
[TBL] [Abstract][Full Text] [Related]
14. VEGF as a biomarker for metastatic uveal melanoma in humans.
Barak V; Pe'er J; Kalickman I; Frenkel S
Curr Eye Res; 2011 Apr; 36(4):386-90. PubMed ID: 21284506
[TBL] [Abstract][Full Text] [Related]
15. Melanoma inhibitory activity: a novel serum marker for uveal melanoma.
Schaller UC; Bosserhoff AK; Neubauer AS; Buettner R; Kampik A; Mueller AJ
Melanoma Res; 2002 Dec; 12(6):593-9. PubMed ID: 12459649
[TBL] [Abstract][Full Text] [Related]
16. sIL-2R- an Immuno-biomarker for Prediction of Metastases in Uveal Melanoma.
Barak V; Kalickman I; Pe'er J
Anticancer Res; 2022 Mar; 42(3):1447-1453. PubMed ID: 35220238
[TBL] [Abstract][Full Text] [Related]
17. Osteopontin as a serologic marker for metastatic uveal melanoma: results of a pilot study.
Reiniger IW; Wolf A; Welge-Lüssen U; Mueller AJ; Kampik A; Schaller UC
Am J Ophthalmol; 2007 Apr; 143(4):705-7. PubMed ID: 17386288
[TBL] [Abstract][Full Text] [Related]
18. S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests.
Missotten GS; Korse CM; van Dehn C; Linders TC; Keunen JE; Jager MJ; Bonfrer JM
Tumour Biol; 2007; 28(2):63-9. PubMed ID: 17264538
[TBL] [Abstract][Full Text] [Related]
19. Nestin expression in primary and metastatic uveal melanoma - possible biomarker for high-risk uveal melanoma.
Djirackor L; Shakir D; Kalirai H; Petrovski G; Coupland SE
Acta Ophthalmol; 2018 Aug; 96(5):503-509. PubMed ID: 29338117
[TBL] [Abstract][Full Text] [Related]
20. PARK7/DJ-1 inhibition decreases invasion and proliferation of uveal melanoma cells.
Lago-Baameiro N; Santiago-Varela M; Camino T; Silva-Rodríguez P; Bande M; Blanco-Teijeiro MJ; Pardo M; Piñeiro A
Tumori; 2023 Feb; 109(1):47-53. PubMed ID: 34918581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]